PROS
MCID: PK3005
MIFTS: 35

Pik3ca-Related Overgrowth Syndrome (PROS)

Categories: Cardiovascular diseases, Fetal diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Pik3ca-Related Overgrowth Syndrome

MalaCards integrated aliases for Pik3ca-Related Overgrowth Syndrome:

Name: Pik3ca-Related Overgrowth Syndrome 59
Pros 59

Classifications:



External Ids:

Orphanet 59 ORPHA530313

Summaries for Pik3ca-Related Overgrowth Syndrome

MalaCards based summary : Pik3ca-Related Overgrowth Syndrome, also known as pros, is related to pik3ca-related overgrowth spectrum and obesity, early-onset, with adrenal insufficiency and red hair. An important gene associated with Pik3ca-Related Overgrowth Syndrome is PIK3CA (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha). The drugs Sirolimus and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include breast, testes and prostate.

Related Diseases for Pik3ca-Related Overgrowth Syndrome

Diseases in the Pik3ca-Related Overgrowth Syndrome family:

Pik3ca-Related Overgrowth Spectrum

Diseases related to Pik3ca-Related Overgrowth Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1793)
# Related Disease Score Top Affiliating Genes
1 pik3ca-related overgrowth spectrum 11.9
2 obesity, early-onset, with adrenal insufficiency and red hair 11.8
3 acute monoblastic leukemia 11.4
4 seborrheic dermatitis 11.4
5 prolidase deficiency 11.4
6 lipoid congenital adrenal hyperplasia 11.4
7 factor xiii deficiency 11.4
8 visceral myopathy 11.1
9 tuftsin deficiency 11.1
10 ectodermal dysplasia and immunodeficiency 2 11.1
11 steel syndrome 11.1
12 lambda 5 deficiency 11.1
13 factor v leiden thrombophilia 11.1
14 prostate cancer 10.9
15 lung cancer 10.9
16 cytokine deficiency 10.8
17 follicular lymphoma 10.8
18 overgrowth syndrome 10.5
19 helix syndrome 10.4
20 ischemia 10.4
21 colorectal cancer 10.4
22 toxic shock syndrome 10.4
23 autoimmune disease 10.4
24 heart disease 10.3
25 chronic kidney disease 10.3
26 ovarian cancer 10.3
27 atherosclerosis susceptibility 10.3
28 lymphocytic leukemia 10.3
29 coronary artery anomaly 10.3
30 rapidly involuting congenital hemangioma 10.3
31 vascular disease 10.3
32 kidney disease 10.3
33 lung disease 10.3
34 breast cancer 10.3
35 inflammatory bowel disease 10.3
36 hyperlipoproteinemia, type iii 10.3
37 acute myocardial infarction 10.3
38 pre-eclampsia 10.3
39 congenital lipomatous overgrowth, vascular malformations, and epidermal nevi 10.3
40 glioblastoma multiforme 10.3
41 glioblastoma 10.3
42 arteries, anomalies of 10.3
43 proteasome-associated autoinflammatory syndrome 1 10.3
44 neuroblastoma 1 10.3
45 brittle bone disorder 10.3
46 hepatocellular carcinoma 10.3
47 col1a1/2-related osteogenesis imperfecta 10.3
48 b-cell lymphoma 10.3
49 periodontitis 10.3
50 alzheimer disease 10.3

Graphical network of the top 20 diseases related to Pik3ca-Related Overgrowth Syndrome:



Diseases related to Pik3ca-Related Overgrowth Syndrome

Symptoms & Phenotypes for Pik3ca-Related Overgrowth Syndrome

Drugs & Therapeutics for Pik3ca-Related Overgrowth Syndrome

Drugs for Pik3ca-Related Overgrowth Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 302)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sirolimus Approved, Investigational Phase 4 53123-88-9 6436030 5284616 46835353
2
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
3
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
4
Capecitabine Approved, Investigational Phase 4 154361-50-9 60953
5
Nicotine Approved Phase 4 54-11-5 942 89594
6
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
7
Metformin Approved Phase 4 657-24-9 4091 14219
8
Zinc Approved, Investigational Phase 4 7440-66-6 32051
9
Insulin glargine Approved Phase 4 160337-95-1
10
Gliclazide Approved Phase 4 21187-98-4 3475
11
Glucagon Approved Phase 4 16941-32-5
12
Lixisenatide Approved Phase 4 320367-13-3
13
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
14
tannic acid Approved Phase 4 1401-55-4
15
Benzocaine Approved, Investigational Phase 4 94-09-7, 1994-09-7 2337
16 Neurotransmitter Agents Phase 4
17 Muscarinic Antagonists Phase 4
18 Cholinergic Agents Phase 4
19 Cholinergic Antagonists Phase 4
20 Tolterodine tartrate Phase 4 124937-52-6
21 Antifungal Agents Phase 4
22 Gastrointestinal Agents Phase 4
23 Autonomic Agents Phase 4
24 Nicotinic Agonists Phase 4
25 Central Nervous System Stimulants Phase 4
26 Antacids Phase 4
27 Proton Pump Inhibitors Phase 4
28 Anti-Ulcer Agents Phase 4
29 Anesthetics Phase 4
30 Peripheral Nervous System Agents Phase 4
31 Central Nervous System Depressants Phase 4
32 Glucagon-Like Peptide 1 Phase 4
33 Insulin, Long-Acting Phase 4
34 Anesthetics, Local Phase 4
35 insulin Phase 4
36 Insulin, Globin Zinc Phase 4
37 Hypoglycemic Agents Phase 4
38
Valganciclovir Approved, Investigational Phase 3 175865-60-8 64147
39
Nintedanib Approved Phase 3 656247-17-5 56843413
40
leucovorin Approved Phase 3 58-05-9 143 6006
41
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
42
Sulfasalazine Approved Phase 3 599-79-1 5359476 5353980
43
Hydroxychloroquine Approved Phase 3 118-42-3 3652
44
Leflunomide Approved, Investigational Phase 3 75706-12-6 3899
45
Testosterone enanthate Approved Phase 2, Phase 3 315-37-7 9416
46
Methyltestosterone Approved Phase 2, Phase 3 58-18-4 6010
47
Testosterone Approved, Experimental, Investigational Phase 2, Phase 3 481-30-1, 58-22-0 6013 10204
48
Testosterone undecanoate Approved, Investigational Phase 2, Phase 3 5949-44-0
49
Tacrolimus Approved, Investigational Phase 3 104987-11-3 445643 439492 6473866
50
Adalimumab Approved Phase 3 331731-18-1 16219006

Interventional clinical trials:

(show top 50) (show all 365)
# Name Status NCT ID Phase Drugs
1 A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients Completed NCT01895335 Phase 4 Teriflunomide
2 A Pilot Study of the Effects of Neutropenia on Patient Reported Outcomes During Chemotherapy With or Without Neulasta® (Pegfilgrastim) in Subjects With Advanced NSCLC Completed NCT00115206 Phase 4 Neulasta® (pegfilgrastim)
3 Assessment of Patient-reported Goal Attainment in the Treatment of Female Overactive Bladder (Phase Ⅳ) Completed NCT00836381 Phase 4 Tolterodine extended-release (ER) 4mg;Placebo
4 An Open Label, randomIzed Controlled Prospective Multicenter Two Arm Phase IV Trial to Determine Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab for Advanced (Inoperable or Metastatic) HER2-negative Hormone Receptor Positive Breast Cancer Completed NCT02248571 Phase 4 Bevacizumab;Capecitabine;Everolimus;Exemestane
5 Identifying Optimal, Translatable Smoking Cessation Intervention Components Completed NCT01122238 Phase 4 Nicotine Patch;Nicotine Gum;Nicotine Patch + Nicotine Gum
6 The Influence of CYP2C19 Genetic Polymorphism and Dosage of Rabeprazole on the Accuracy of Proton-Pump Inhibitor Testing in Chinese Patients With Gastroesophageal Reflux Disease Completed NCT00354757 Phase 4 rabeprazole
7 An Open-Label, Single-Arm Phase IV Study To Assess Ocrelizumab Efficacy, Safety, And Impact On Patient Reported Outcomes (PROS) In Patients With Active Relapsing Multiple Sclerosis Recruiting NCT03589105 Phase 4 Ocrelizumab 300 mg;Ocrelizumab 600 mg
8 Variability of Glucose Assessed in a Randomized Trial Comparing the Initiation of A Treatment Approach With Biosimilar Basal Insulin Analog Or a Titratable iGlarLixi combinatioN in Type 2 Diabetes Among South Asian Subjects (VARIATION 2 SA Trial) Recruiting NCT03819790 Phase 4 Basal insulin glargine and lixisenatide;Basal insulin Basaglar/Lantus + gliclazide MR;Metformin
9 Quality of Life in Patients With Non-adipocyte Soft Tissue Sarcoma Under Palliative Chemotherapy or Pazopanib — a Randomized, Controlled Trial Recruiting NCT03735758 Phase 4 Pazopanib or chemotherapy
10 Interscalene Single Shot With Plain Bupivacaine Versus Liposomal Bupivacaine for Arthroscopic Shoulder Surgery Recruiting NCT03638960 Phase 4 Bupivacaine liposome;Bupivacaine Hydrochloride
11 A Multicenter, Open-label Phase IV Study to Evaluate Whether a Medication Event Monitoring System (MEMS®) Can Improve Adherence to Tecfidera® (Delayed-release Dimethyl Fumarate) Treatment in Multiple Sclerosis Patients. Terminated NCT02343159 Phase 4 dimethyl fumarate
12 Tight Intra-Operative Glucose Control Using Continuous Insulin Infusion During Coronary Artery Bypass Surgery: Randomized Controlled Trial Terminated NCT00394303 Phase 4 Intraoperative continuous insulin infusion
13 A Multicenter, Open-Label Study to Evaluate Fatigue in Subjects With Relapsing-Remitting Multiple Sclerosis During Treatment With Tecfidera® (Dimethyl Fumarate) Gastro-Resistant Hard Capsules (TECNERGY) Withdrawn NCT02090348 Phase 4 dimethyl fumarate
14 Community Interventions in Non-Medical Settings to Increase Informed Decision Making for Prostate Cancer Screening - Harvard - SIP 21-04 Unknown status NCT00207636 Phase 3
15 Efficacy and Safety of Anti-cytomegalovirus Prophylaxis Versus Pre-emptive Approaches With Valganciclovir in Heart Transplant Recipients Treated With Everolimus or Mycophenolate. A Randomized Open-label Study for Prevention of Cardiaca Allograft Vasculopathy Unknown status NCT00966836 Phase 3 Pre-emptive strategy with valganciclovir plus everolimus;Prophylaxis with valganciclovir plus mycophenolate;Prophylaxis with valganciclovir plus everolimus;Pre-emptive mycophenolate
16 A Six Month Double Blind Randomized Placebo Controlled Trial Followed by Each Arm Being Converted to Oral Nintedanib 150 mg Twice Daily Comparing the Effect on High Resolution Computerized Tomography Quantitative Lung Fibrosis Score, Lung Function, Six Minute Walk Test Distance and St. George's Respiratory Questionnaire After Six Months of Treatment in Patients With Idiopathic Pulmonary Fibrosis With Continued Evaluations Over a Period of up to Eighteen Months Completed NCT01979952 Phase 3 Matching Placebo;Nintedanib
17 A Randomized, Double-blind, Parallel, Placebo-controlled Study Assessing the Efficacy and Safety of Sarilumab Added to Non-biologic DMARD Therapy in Patients With Rheumatoid Arthritis Who Are Inadequate Responders to or Intolerant of TNF-α Antagonists Completed NCT01709578 Phase 3 Sarilumab;placebo;hydroxychloroquine;methotrexate;sulfasalazine;leflunomide
18 New Acute Treatment for Stroke - The Effect of Remote PERconditioning Completed NCT00975962 Phase 3 Actilyse
19 Ph3,DB/DD,Multi-Ctr,Pros,Rand Study-Efficacy and Safety of LCP-Tacro™ Tablets, QD, Compared to Prograf® Capsules,BID, in Combination With Mycophenolate Mofetil for Acute Allograft Rejection in De Novo Kidney Transplant Completed NCT01187953 Phase 3 Prograf (tacrolimus);LCP-Tacro
20 Ph3, Open Label, Multi-Ctr, Pros, Rand Study -Efficacy and Safety, Conversion Prograf® Capsules BID to LCPTacro Tablets QD, for Prevent of Acute Allograft Rejection in Stable Kidney Transplant pt. Completed NCT00817206 Phase 3 LCP-Tacro;Prograf
21 Dose Response Effects of Exogenous Testosterone on the Prostate and Comparison With Effects on Body Composition (Short Title: PROS-2) Completed NCT01327495 Phase 2, Phase 3 Testosterone 1% gel 1.25 g;Testosterone 1% gel 2.5 g;Testosterone 1% gel 5.0 g;testosterone 1% gel 10 g;testosterone 1% gel 15 g;Acyline
22 Telephone and Web-based Teen Tobacco Cessation in HMOs Completed NCT00311948 Phase 3
23 Efficacy/Effectiveness of Unhealthy Drug Use Screening/Brief Intervention Models Completed NCT00876941 Phase 3
24 ASPIRE: DETERIMINING THE IMPACT OF CRISABOROLE (Eucrisa) AND TACROLIMUS 0.03% ON PATIENT-REPORTED OUTCOMES AND CAREGIVER BURDEN IN CHILDREN WITH ATOPIC DERMATITIS Recruiting NCT03645057 Phase 3 Crisaborole;Tacrolimus 0.03% Ointment
25 A Phase 3, 56-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Utilizing Patient-Reported and Radiographic Outcomes to Evaluate the Efficacy and Safety of a Single Injection of SM04690 Injected in the Target Knee Joint of Moderately to Severely Symptomatic Osteoarthritis Subjects Recruiting NCT03928184 Phase 3 Lorecivivint;Placebo
26 A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Children 6 to <12 Years of Age With Uncontrolled Persistent Asthma Recruiting NCT02948959 Phase 3 Dupilumab;Asthma Controller Therapies (incl. prednisone/prednisolone);Asthma Reliever Therapies
27 Clinical, Radiological and Patient Perceived Outcome After Total Wrist Arthroplasty With a New Total Wrist Arthroplasty Implant Recruiting NCT02336009 Phase 2, Phase 3
28 A Phase 3b, Multicenter, Randomized, Blinded, Active-Controlled Study to Compare the Efficacy and Safety of Ustekinumab to That of Adalimumab in the Treatment of Biologic Naïve Subjects With Moderately-to-Severely Active Crohn's Disease Recruiting NCT03464136 Phase 3
29 A Phase 3b, Randomized, Double-blind, Multicenter Study to Evaluate the Safety and Efficacy of Intravenous Re-induction Therapy With Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Recruiting NCT03782376 Phase 3 Ustekinumab approximately 6 mg/kg (IV);Placebo (SC);Placebo (IV);Ustekinumab 90 mg (SC) Group 1;Ustekinumab 90 mg (SC) Group 2
30 Pros & Cons of Norepinephrine Infusion Versus Midodrine & Octreotide in Patients With Hepatorenal Syndrome Type 1 in Intensive Care Unit. Recruiting NCT03455322 Phase 2, Phase 3 norepinephrine versus midodrine & octreotide
31 Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer (Study SWOG/NRG 1806) Recruiting NCT03775265 Phase 3 Atezolizumab;Cisplatin;Fluorouracil;Gemcitabine;Mitomycin
32 A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Dupilumab in Chinese Adult Patients With Moderate to Severe Atopic Dermatitis Active, not recruiting NCT03912259 Phase 3 dupilumab SAR231893;placebo;Emollient (moisturizer)
33 A Phase 3, Randomized, Active Controlled Study to Evaluate Maintenance of Response, Safety and Patient Reported Outcomes in Acromegaly Patients Treated With Octreotide Capsules vs. Parenteral Somatostatin Receptor Ligands Active, not recruiting NCT02685709 Phase 3 Octreotide capsules;Injectable Somatostatin Analogs (octreotide or lanreotide);Cabergoline
34 A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin/Bevacizumab in Platinum Resistant Ovarian Cancer Suspended NCT02839707 Phase 2, Phase 3 Atezolizumab;Pegylated Liposomal Doxorubicin Hydrochloride
35 The Efficacy of Intravenous Iron for the Treatment of Anemia in Cancer Patients Unknown status NCT02599012 Phase 2 Ferinject®
36 Phase 1 Study of Herb Yuyang Ointment That Expressed Good Effect in Diabetic Foot Ulcer Unknown status NCT00839865 Phase 2 herb ointment
37 Adaptation and Evaluation of the Honest Open Proud Program for Adolescents With Mental Illness Completed NCT02751229 Phase 2
38 BrUOG-PROS-221 Neoadjuvant Weekly Ixabepilone for High Risk, Clinically Localized Prostate Cancer: A Phase II Study Completed NCT00828308 Phase 2 Ixabepilone
39 Nonrandomized Open Label Pilot Study of Sirolimus Therapy for Segmental Overgrowth Caused by Somatic PI3K Activation Completed NCT02428296 Phase 2 Sirolimus
40 HealthCall: Brief Intervention to Reduce Drug Use in HIV Primary Care Completed NCT01312181 Phase 2
41 Computer-based Brief Intervention for Perinatal Drug, Alcohol, and Tobacco Abuse Completed NCT00685074 Phase 1, Phase 2
42 Phase II Study of Comprehensive Patient Reported Outcomes (PRO) Management for Oncology Practice Completed NCT01108315 Phase 1, Phase 2
43 Phase II Randomized Controlled Trial of Rapid and Easy Strength Training to Preserve Function in Late Stage Cancer Completed NCT01334983 Phase 2
44 Feasibility, Efficacy and Safety of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) With Cisplatin and Doxorubicin in Patients With Gastric Cancer and Peritoneal Carcinomatosis: an Open-label, Single-arm, Phase II Clinical Trial Completed NCT01854255 Phase 2 doxorubicin and cisplatin
45 A Randomized, Double-blind, Placebo Controlled Study to Evaluate the Safety, Tolerability and Clinical Effect of Oral Danirixin (GSK1325756) in the Treatment of Healthy Adults With Acute, Uncomplicated Influenza (201682) Completed NCT02469298 Phase 2 GSK1325756 (Danirixin);Placebo To Match GSK1325756;Oseltamivir Phosphate;Placebo To Match Oseltamivir Phosphate
46 Biomarkers of Lupus Disease: Study of Biomarker Changes Before and After Treatment With Depomedrol and Background Medication Withdrawal in Patients With Mild to Moderate SLE Disease Activity Completed NCT00987831 Phase 1, Phase 2 Group A SLE prospective study
47 Alcohol Use Reduction in Methadone Individuals With HCV Completed NCT00958763 Phase 2
48 Motivating Treatment Seeking and Behavior Change by Untreated Military Personnel Abusing Alcohol or Drugs Completed NCT01128140 Phase 2
49 Internet-Based Nonsmoking Program for Postpartum Women Completed NCT02602730 Phase 2
50 Screening and Brief Intervention in the ED Among Mexican-origin Young Adults Completed NCT02056535 Phase 2

Search NIH Clinical Center for Pik3ca-Related Overgrowth Syndrome

Genetic Tests for Pik3ca-Related Overgrowth Syndrome

Anatomical Context for Pik3ca-Related Overgrowth Syndrome

MalaCards organs/tissues related to Pik3ca-Related Overgrowth Syndrome:

41
Breast, Testes, Prostate, Lung, Brain, Heart, Kidney

Publications for Pik3ca-Related Overgrowth Syndrome

Articles related to Pik3ca-Related Overgrowth Syndrome:

(show top 50) (show all 9769)
# Title Authors PMID Year
1
A review of bioanalytical techniques for evaluation of cannabis (Marijuana, weed, Hashish) in human hair. 38
31428743 2019
2
Application of magnetic field improves growth, yield and fruit quality of tomato irrigated alternatively by fresh and agricultural drainage water. 38
31200197 2019
3
Improvements in productivity and increased participation in daily activities over 52 weeks of certolizumab pegol treatment of rheumatoid arthritis: results of a Belgian observational study. 38
30160189 2019
4
Contemporary management of adnexa at the time of benign hysterectomy: a review of the literature. 38
31303119 2019
5
CRISPR-Cas9 system: A new-fangled dawn in gene editing. 38
31295471 2019
6
What we know and what we think we know: Revealing misconceptions about coastal management for sandy beaches along the U.S. Atlantic Seaboard. 38
31150904 2019
7
Patients undergoing hip arthroscopy with active workers' compensation claims do not demonstrate inferior outcomes at mid-term. 38
30442020 2019
8
The impact on adolescents of a Transtheoretical Model-based programme on fruit and vegetable consumption. 38
31171047 2019
9
Long-term Patient-reported Outcomes Following Postmastectomy Breast Reconstruction: An 8-year Examination of 3268 Patients. 38
31356276 2019
10
Valorisation of the invasive species, Prosopis juliflora, using the carboxylate platform to produce volatile fatty acids. 38
31195362 2019
11
Patellar tendon shortening following patellofemoral joint replacement. 38
30315337 2019
12
In-vivo optogenetics and pharmacology in deep intracellular recordings. 38
31288037 2019
13
FDA's and EMA's approval of brentuximab vedotin for advanced Hodgkin lymphoma: Another player in the town? 38
31166030 2019
14
Comparative charge-based separation study with various capillary electrophoresis (CE) modes and cation exchange chromatography (CEX) for the analysis of monoclonal antibodies. 38
31228849 2019
15
Correction for Item Response Theory Latent Trait Measurement Error in Linear Mixed Effects Models. 38
31183670 2019
16
Comparing success rates of the Hayman compression suture and the Bakri balloon tamponade. 38
29558231 2019
17
QuEChERS - Fundamentals, relevant improvements, applications and future trends. 38
31103162 2019
18
Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study. 38
31096006 2019
19
Impact of severe hypoglycaemia on psychological outcomes in adults with Type 2 diabetes: a systematic review. 38
31271669 2019
20
Protective effects of distinct proline-rich oligopeptides from B. jararaca snake venom against oxidative stress-induced neurotoxicity. 38
31181294 2019
21
Engineering and design considerations for next-generation snakebite antivenoms. 38
31173790 2019
22
Municipality-based pragmatic rehabilitation stratified in accordance with individual needs-results from a longitudinal survey study. 38
31375907 2019
23
MCEE 2.0: more options and enhanced performance. 38
31278548 2019
24
Comparative Analysis of Diaphyseal versus Metaphyseal tracker Placement in Imageless Navigation Systems for Total Knee Arthroplasty. 38
31378861 2019
25
[German linguistic validation of the BODY-Q: standardised PRO instrument after bariatric and bodycontouring surgery]. 38
30669169 2019
26
Alcohol Use and Ethnicity Independently Predict Antiretroviral Therapy Nonadherence Among Patients Living with HIV/HCV Coinfection. 38
31435855 2019
27
Meaningful Patient-centered Outcomes 1 Year Following Cardiac Surgery. 38
31397691 2019
28
Potential pros and cons of the real-time feedback mechanism embedded in smartwatches. 38
31401134 2019
29
Reply to: Potential pros and cons of the real-time feedback mechanism embedded in smartwatches. 38
31401137 2019
30
Pros and cons of 5-HT3 receptor antagonists in neuropsychiatric diseases. 38
31402188 2019
31
Controversies on the endoscopic and surgical management of pain in patients with chronic pancreatitis: pros and cons! 38
31129569 2019
32
Primum non nocere in early nutrition therapy during critical illness: Balancing the pros and cons of early very high protein administration. 38
31072664 2019
33
Restoring thymic function: Then and now. 38
31108430 2019
34
Predictors of Patient-Reported Outcomes at 2 Years After Revision Anterior Cruciate Ligament Reconstruction. 38
31318611 2019
35
A deliberate choice? Exploring factors related to informed decision-making about childhood vaccination among acceptors, refusers, and partial acceptors. 38
31383488 2019
36
Effect of smoking status on lung function, patient-reported outcomes, and safety among patients with COPD treated with indacaterol/glycopyrrolate: Pooled analysis of the FLIGHT1 and FLIGHT2 studies. 38
31344660 2019
37
Evaluation of photoreceptor outer segment length in hydroxychloroquine users. 38
30932033 2019
38
Big data analysis of associations between patient reported outcomes, observer reported toxicities, and overall quality of life in head and neck cancer patients treated with radiation therapy. 38
31128357 2019
39
Cancer survivor perspectives on sharing patient-generated health data with central cancer registries. 38
31399859 2019
40
A critical review of zebrafish schizophrenia models: time for validation? 38
31381931 2019
41
The Effect of Symptom Duration on Outcomes After Fusion for Degenerative Spondylolisthesis. 38
31431870 2019
42
Analysis of PROC and PROS1 single nucleotide polymorphisms in a thrombophilia family. 38
31295762 2019
43
Patient-reported quality of life with obesity - development of a new measurement scale. 38
31429227 2019
44
Review: Patient-reported outcomes in multiple sclerosis care. 38
31154262 2019
45
Validation of Neuro-QoL and PROMIS Mental Health Patient Reported Outcome Measures in Persons with Huntington Disease. 38
31424415 2019
46
Conducting Online Surveys. 38
31084575 2019
47
Comparison of Semiconducting Polymer Dots and Semiconductor Quantum Dots for Smartphone-Based Fluorescence Assays. 38
31403282 2019
48
Strategies for interventional therapies in cancer-related pain-a crossroad in cancer pain management. 38
31093769 2019
49
Intermittent or continuous feeding: any difference during the first week? 38
31107308 2019
50
Family presence during resuscitation: A narrative review of the practices and views of critical care nurses. 38
31053336 2019

Variations for Pik3ca-Related Overgrowth Syndrome

Expression for Pik3ca-Related Overgrowth Syndrome

Search GEO for disease gene expression data for Pik3ca-Related Overgrowth Syndrome.

Pathways for Pik3ca-Related Overgrowth Syndrome

GO Terms for Pik3ca-Related Overgrowth Syndrome

Sources for Pik3ca-Related Overgrowth Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....